Cytogénétique Hématologique (GFCH) d'Hématologie Cellulaire (GFHC) and the Groupe Français de gene mutations: a report of 59 cases by the Groupe Français M0 AML, clinical and biologic features of the disease, includingAML1

[1]  C. Preudhomme,et al.  New mechanisms of AML1 gene alteration in hematological malignancies , 2003, Leukemia.

[2]  G. Ehninger,et al.  Analysis of Flt3-activating Mutations in 979 Patients with Acute Myelogenous Leukemia: Association with Fab Subtypes and Identification of Subgroups with Poor Prognosis , 2022 .

[3]  J. V. van Dongen,et al.  Basic helix-loop-helix proteins E2A and HEB induce immature T-cell receptor rearrangements in nonlymphoid cells. , 2001, Blood.

[4]  Claudia Schoch,et al.  Acute myeloid leukaemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients , 2001, British journal of haematology.

[5]  G. Morgan,et al.  Mutations in the AML1 gene in acute myeloid leukaemia patients with FAB types M0 and M7. , 2000 .

[6]  E. Macintyre,et al.  Rapid, multifluorescent TCRG Vγ and Jγ typing: application to T cell acute lymphoblastic leukemia and to the detection of minor clonal populations , 2000, Leukemia.

[7]  E. Macintyre,et al.  High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. , 2000, Blood.

[8]  T. Naoe,et al.  Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. , 1999, Blood.

[9]  H. Yamasaki,et al.  Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. , 1999, Blood.

[10]  K. Tanaka,et al.  TLE, the human homolog of groucho, interacts with AML1 and acts as a repressor of AML1-induced transactivation. , 1998, Biochemical and biophysical research communications.

[11]  Z. Paroush,et al.  Transcriptional repression by AML1 and LEF-1 is mediated by the TLE/Groucho corepressors. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[12]  H. Tien,et al.  CD7 positive hematopoietic progenitors and acute myeloid leukemia and other minimally differentiated leukemia. , 1998, Leukemia & lymphoma.

[13]  F. Davi,et al.  Early onset of immunoglobulin heavy chain gene rearrangements in normal human bone marrow CD34+ cells. , 1997, Blood.

[14]  M. Krangel,et al.  Regulation of  T Cell Receptor δ Gene Rearrangement by CBF/PEBP2 , 1997, The Journal of experimental medicine.

[15]  G. Papa,et al.  Minimally differentiated acute myeloid leukemia (AML-M0): comparison of 25 cases with other French-American-British subtypes. , 1997, Blood.

[16]  P. Cony-Makhoul,et al.  Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study. , 1996, Leukemia.

[17]  G. Leverger,et al.  Simplified strategies for minimal residual disease detection in B‐cell precursor acute lymphoblastic leukaemia , 1996, British journal of haematology.

[18]  P. Hurteloup,et al.  Treatment of acute myeloblastic leukemia in adults. The GOELAM experience. , 1996, Hematology and cell therapy.

[19]  R. Zittoun.  The EORTC trials for acute myelogenous leukemia , 1996 .

[20]  M. Tribalto,et al.  Minimally differentiated acute myeloid leukemia (AML-MO): a distinct clinico-biologic entity with poor prognosis , 1996, Annals of Hematology.

[21]  G. Papa,et al.  Biological profile of 23 cases of minimally differentiated acute myeloid leukemia (AML-M0) and its clinical implications. , 1996, Blood.

[22]  A Orfao,et al.  Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). , 1995, Leukemia.

[23]  P. Cin,et al.  Cytogenetic profile of minimally differentiated (FAB M0) acute myeloid leukemia: correlation with clinicobiologic findings. , 1995, Blood.

[24]  M. Tribalto,et al.  Minimally differentiated acute myeloid leukaemia (AML‐MO): cytochemical, immunophenotypic and cytogenetic analysis of 19 cases , 1994, British journal of haematology.

[25]  H. Cavé,et al.  Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T-cell receptor genes. , 1994, Blood.

[26]  P. Fenaux,et al.  Place de la double induction dans le traitement des leucémies aiguës myéloblastiques de l'adulte : résultats intermédiaires du protocole LAM90 , 1994 .

[27]  J. Testa,et al.  Minimally differentiated acute nonlymphocytic leukemia: a distinct entity. , 1987, Blood.